- +1 858 909 0079
- +1 858 909 0057
- [email protected]
- +1 858 909 0079
- [email protected]
Cat# | Products (Recombinant protein) | Swiss Prot# | Size | Price (US$) | Order |
PL0577 | Recombinant protein-Plasmodium yoelii nigeriensis Erythrocyte-binding-like protein (a.a.61 to 460) | B5U9X9 | 100 µg | 1195 | |
PL0578 | Recombinant protein-Plasmodium yoelii Apical membrane antigen-1 (a.a.18 to 145) | A7LBG0 | 100 µg | 1195 | |
PL0579 | Recombinant protein-Plasmodium yoelii Erythrocyte-binding-like protein (a.a.61 to 460) | B5U9X6 | 100 µg | 1195 | |
PL0580 | Recombinant protein-Plasmodium yoelii Transmission-blocking target antigen s230 (a.a.61 to 469) | Q7RKE2 | 100 µg | 1195 | |
PL0581 | Recombinant protein-Plasmodium yoelii Processed variable antigen-related (a.a.61 to 460) | Q7RB34 | 100 µg | 1195 | |
PL0582 | Recombinant protein-Plasmodium yoelii Octapeptide-repeat antigen (a.a.61 to 460) | Q7RBY7 | 100 µg | 1195 | |
PL0583 | Recombinant protein-Plasmodium yoelii Tryptophan-threonine-rich antigen (a.a.61 to 424) | Q7RES9 | 100 µg | 1195 | |
PL0584 | Recombinant protein-Plasmodium yoelii STARP antigen (a.a.21 to 312) | Q7RSY4 | 100 µg | 1195 | |
PL0585 | Recombinant protein-Plasmodium yoelii Secreted blood-stage antigen pAg-3 (a.a.21 to 354) | Q7RIJ4 | 100 µg | 1195 | |
PL0586 | Recombinant protein-Plasmodium yoelii Erythrocyte membrane-associated antigen (a.a.61 to 460) | Q7R9A5 | 100 µg | 1195 | |
PL0587 | Recombinant protein-Plasmodium yoelii Synthetic antigen (a.a.61 to 467) | Q7RPG4 | 100 µg | 1195 | |
PL0588 | Recombinant protein-Plasmodium yoelii Protective antigen-related (a.a.32 to 106) | Q7R947 | 100 µg | 1195 | |
PL0589 | Recombinant protein-Plasmodium yoelii Hepatocellular carcinoma-associated antigen 56A (a.a.61 to 460) | Q7RH73 | 100 µg | 1195 | |
PL0590 | Recombinant protein-Plasmodium yoelii C-13 antigen-related (a.a.61 to 460) | Q7RLX0 | 100 µg | 1195 | |
PL0591 | Recombinant protein-Plasmodium yoelii Synthetic antigen of (a.a.21 to 282) | Q7RJE4 | 100 µg | 1195 | |
PL0592 | Recombinant protein-Plasmodium yoelii S-antigen protein (a.a.61 to 460) | Q7RN90 | 100 µg | 1195 | |
PL0593 | Recombinant protein-Plasmodium yoelii Seroreactive antigen BMN1-9B-related (a.a.61 to 460) | Q7RIW5 | 100 µg | 1195 | |
PL0594 | Recombinant protein-Plasmodium yoelii Malaria antigen-related (a.a.61 to 460) | Q7RGA2 | 100 µg | 1195 | |
PL0595 | Recombinant protein-Plasmodium yoelii Apical membrane antigen-1 (a.a.61 to 460) | Q7RP78 | 100 µg | 1195 | |
PL0596 | Recombinant protein-Plasmodium yoelii Erythrocyte membrane-associated antigen (a.a.61 to 460) | Q7RAJ7 | 100 µg | 1195 | |
PL0597 | Recombinant protein-Plasmodium yoelii hepatocyte erythrocyte protein 17 kDa (a.a.24 to 169) | Q7RGC6 | 100 µg | 1195 | |
PL0598 | Recombinant protein-Plasmodium yoelii Mature-parasite-infected erythrocyte surface antigen (a.a.61 to 460) | Q7RBX2 | 100 µg | 1195 | |
PL0599 | Recombinant protein-Plasmodium yoelii infected erythrocyte surface antigen (a.a.47 to 343) | Q7RS89 | 100 µg | 1195 | |
PL0600 | Recombinant protein-Plasmodium yoelii Sporozoite surface protein 2 (a.a.61 to 460) | Q01443 | 100 µg | 1195 | |
PL0601 | Recombinant protein-Plasmodium yoelii C-13 antigen (a.a.61 to 504) | Q7REB1 | 100 µg | 1195 | |
PL0602 | Recombinant protein-Plasmodium yoelii Erythrocyte membrane-associated antigen (a.a.61 to 460) | Q7RBN0 | 100 µg | 1195 | |
PL0603 | Recombinant protein-Plasmodium yoelii Merozoite surface protein 1-Py230 (a.a.61 to 460) | P13828 | 100 µg | 1195 | |
PL0604 | Recombinant protein-Plasmodium yoelii Erythrocyte membrane-associated giant protein antigen (a.a.61 to 460) | Q7RJB3 | 100 µg | 1195 | |
PL0605 | Recombinant protein-Plasmodium yoelii Plasmodium falciparum antigen 332 (a.a.61 to 460) | Q7RS33 | 100 µg | 1195 | |
PL0606 | Recombinant protein-Plasmodium yoelii Ring-infested erythrocyte surface antigen (a.a.31 to 393) | Q7RC47 | 100 µg | 1195 | |
PL0607 | Recombinant protein-Plasmodium yoelii Mature-parasite-infected erythrocyte surface antigen (a.a.61 to 460) | Q7RN42 | 100 µg | 1195 | |
PL0608 | Recombinant protein-Plasmodium yoelii Ookinete surface antigen-like protein Pfs28 (a.a.16 to 227) | Q7KJ23 | 100 µg | 1195 | |
PL0609 | Recombinant protein-Plasmodium yoelii Mature-parasite-infected erythrocyte surface antigen (a.a.61 to 472) | Q7RME2 | 100 µg | 1195 | |
PL0610 | Recombinant protein-Plasmodium yoelii Processed variable antigen (a.a.31 to 414) | Q7RHD2 | 100 µg | 1195 | |
PL0611 | Recombinant protein-Plasmodium yoelii Duffy receptor- beta form (a.a.61 to 460) | Q7RFE3 | 100 µg | 1195 | |
PL0612 | Recombinant protein-Plasmodium yoelii Synthetic antigen of (a.a.61 to 523) | Q7RFF4 | 100 µg | 1195 | |
PL0613 | Recombinant protein-Plasmodium yoelii Transplantation antigen p35b-related (a.a.21 to 212) | Q7RN99 | 100 µg | 1195 | |
PL0614 | Recombinant protein-Plasmodium yoelii Ring-infected erythrocyte surface antigen (a.a.31 to 390) | Q7RH32 | 100 µg | 1195 | |
PL0615 | Recombinant protein-Plasmodium yoelii Latent nuclear antigen-related (a.a.18 to 139) | Q7RBE8 | 100 µg | 1195 | |
PL0616 | Recombinant protein-Plasmodium yoelii Malaria antigen (a.a.61 to 460) | Q7RRF2 | 100 µg | 1195 | |
PL0617 | Recombinant protein-Plasmodium yoelii Ring-infested erythrocyte surface antigen (a.a.21 to 259) | Q7RMC1 | 100 µg | 1195 | |
PL0618 | Recombinant protein-Plasmodium yoelii Ring-infested erythrocyte surface antigen (a.a.61 to 515) | Q7RCW5 | 100 µg | 1195 | |
PL0619 | Recombinant protein-Plasmodium yoelii 19 kDa sporozoite antigen (a.a.24 to 211) | Q7RJQ1 | 100 µg | 1195 | |
PL0620 | Recombinant protein-Plasmodium yoelii 41-2 protein antigen-related (a.a.18 to 115) | Q7RE91 | 100 µg | 1195 | |
PL0621 | Recombinant protein-Plasmodium yoelii Protective antigen-related (a.a.21 to 316) | Q7RGF9 | 100 µg | 1195 | |
PL0622 | Recombinant protein-Plasmodium yoelii Ring-infected erythrocyte surface antigen (a.a.61 to 460) | Q7R903 | 100 µg | 1195 | |
PL0623 | Recombinant protein-Plasmodium yoelii Ring-infested erythrocyte surface antigen (a.a.61 to 460) | Q7RLL4 | 100 µg | 1195 | |
RPL0577 | cDNA-Plasmodium yoelii nigeriensis Erythrocyte-binding-like protein (a.a.61 to 460) | B5U9X9 | 2 µg | 2394 | |
RPL0578 | cDNA-Plasmodium yoelii Apical membrane antigen-1 (a.a.18 to 145) | A7LBG0 | 2 µg | 762 | |
RPL0579 | cDNA-Plasmodium yoelii Erythrocyte-binding-like protein (a.a.61 to 460) | B5U9X6 | 2 µg | 2394 | |
RPL0580 | cDNA-Plasmodium yoelii Transmission-blocking target antigen s230 (a.a.61 to 469) | Q7RKE2 | 2 µg | 2448 | |
RPL0581 | cDNA-Plasmodium yoelii Processed variable antigen-related (a.a.61 to 460) | Q7RB34 | 2 µg | 2394 | |
RPL0582 | cDNA-Plasmodium yoelii Octapeptide-repeat antigen (a.a.61 to 460) | Q7RBY7 | 2 µg | 2394 | |
RPL0583 | cDNA-Plasmodium yoelii Tryptophan-threonine-rich antigen (a.a.61 to 424) | Q7RES9 | 2 µg | 2178 | |
RPL0584 | cDNA-Plasmodium yoelii STARP antigen (a.a.21 to 312) | Q7RSY4 | 2 µg | 1746 | |
RPL0585 | cDNA-Plasmodium yoelii Secreted blood-stage antigen pAg-3 (a.a.21 to 354) | Q7RIJ4 | 2 µg | 1998 | |
RPL0586 | cDNA-Plasmodium yoelii Erythrocyte membrane-associated antigen (a.a.61 to 460) | Q7R9A5 | 2 µg | 2394 | |
RPL0587 | cDNA-Plasmodium yoelii Synthetic antigen (a.a.61 to 467) | Q7RPG4 | 2 µg | 2436 | |
RPL0588 | cDNA-Plasmodium yoelii Protective antigen-related (a.a.32 to 106) | Q7R947 | 2 µg | 800 | |
RPL0589 | cDNA-Plasmodium yoelii Hepatocellular carcinoma-associated antigen 56A (a.a.61 to 460) | Q7RH73 | 2 µg | 2394 | |
RPL0590 | cDNA-Plasmodium yoelii C-13 antigen-related (a.a.61 to 460) | Q7RLX0 | 2 µg | 2394 | |
RPL0591 | cDNA-Plasmodium yoelii Synthetic antigen of (a.a.21 to 282) | Q7RJE4 | 2 µg | 1566 | |
RPL0592 | cDNA-Plasmodium yoelii S-antigen protein (a.a.61 to 460) | Q7RN90 | 2 µg | 2394 | |
RPL0593 | cDNA-Plasmodium yoelii Seroreactive antigen BMN1-9B-related (a.a.61 to 460) | Q7RIW5 | 2 µg | 2394 | |
RPL0594 | cDNA-Plasmodium yoelii Malaria antigen-related (a.a.61 to 460) | Q7RGA2 | 2 µg | 2394 | |
RPL0595 | cDNA-Plasmodium yoelii Apical membrane antigen-1 (a.a.61 to 460) | Q7RP78 | 2 µg | 2394 | |
RPL0596 | cDNA-Plasmodium yoelii Erythrocyte membrane-associated antigen (a.a.61 to 460) | Q7RAJ7 | 2 µg | 2394 | |
RPL0597 | cDNA-Plasmodium yoelii hepatocyte erythrocyte protein 17 kDa (a.a.24 to 169) | Q7RGC6 | 2 µg | 870 | |
RPL0598 | cDNA-Plasmodium yoelii Mature-parasite-infected erythrocyte surface antigen (a.a.61 to 460) | Q7RBX2 | 2 µg | 2394 | |
RPL0599 | cDNA-Plasmodium yoelii infected erythrocyte surface antigen (a.a.47 to 343) | Q7RS89 | 2 µg | 1776 | |
RPL0600 | cDNA-Plasmodium yoelii Sporozoite surface protein 2 (a.a.61 to 460) | Q01443 | 2 µg | 2394 | |
RPL0601 | cDNA-Plasmodium yoelii C-13 antigen (a.a.61 to 504) | Q7REB1 | 2 µg | 2658 | |
RPL0602 | cDNA-Plasmodium yoelii Erythrocyte membrane-associated antigen (a.a.61 to 460) | Q7RBN0 | 2 µg | 2394 | |
RPL0603 | cDNA-Plasmodium yoelii Merozoite surface protein 1-Py230 (a.a.61 to 460) | P13828 | 2 µg | 2394 | |
RPL0604 | cDNA-Plasmodium yoelii Erythrocyte membrane-associated giant protein antigen (a.a.61 to 460) | Q7RJB3 | 2 µg | 2394 | |
RPL0605 | cDNA-Plasmodium yoelii Plasmodium falciparum antigen 332 (a.a.61 to 460) | Q7RS33 | 2 µg | 2394 | |
RPL0606 | cDNA-Plasmodium yoelii Ring-infested erythrocyte surface antigen (a.a.31 to 393) | Q7RC47 | 2 µg | 2172 | |
RPL0607 | cDNA-Plasmodium yoelii Mature-parasite-infected erythrocyte surface antigen (a.a.61 to 460) | Q7RN42 | 2 µg | 2394 | |
RPL0608 | cDNA-Plasmodium yoelii Ookinete surface antigen-like protein Pfs28 (a.a.16 to 227) | Q7KJ23 | 2 µg | 1266 | |
RPL0609 | cDNA-Plasmodium yoelii Mature-parasite-infected erythrocyte surface antigen (a.a.61 to 472) | Q7RME2 | 2 µg | 2466 | |
RPL0610 | cDNA-Plasmodium yoelii Processed variable antigen (a.a.31 to 414) | Q7RHD2 | 2 µg | 2298 | |
RPL0611 | cDNA-Plasmodium yoelii Duffy receptor- beta form (a.a.61 to 460) | Q7RFE3 | 2 µg | 2394 | |
RPL0612 | cDNA-Plasmodium yoelii Synthetic antigen of (a.a.61 to 523) | Q7RFF4 | 2 µg | 2772 | |
RPL0613 | cDNA-Plasmodium yoelii Transplantation antigen p35b-related (a.a.21 to 212) | Q7RN99 | 2 µg | 1146 | |
RPL0614 | cDNA-Plasmodium yoelii Ring-infected erythrocyte surface antigen (a.a.31 to 390) | Q7RH32 | 2 µg | 2154 | |
RPL0615 | cDNA-Plasmodium yoelii Latent nuclear antigen-related (a.a.18 to 139) | Q7RBE8 | 2 µg | 726 | |
RPL0616 | cDNA-Plasmodium yoelii Malaria antigen (a.a.61 to 460) | Q7RRF2 | 2 µg | 2394 | |
RPL0617 | cDNA-Plasmodium yoelii Ring-infested erythrocyte surface antigen (a.a.21 to 259) | Q7RMC1 | 2 µg | 1428 | |
RPL0618 | cDNA-Plasmodium yoelii Ring-infested erythrocyte surface antigen (a.a.61 to 515) | Q7RCW5 | 2 µg | 2724 | |
RPL0619 | cDNA-Plasmodium yoelii 19 kDa sporozoite antigen (a.a.24 to 211) | Q7RJQ1 | 2 µg | 1122 | |
RPL0620 | cDNA-Plasmodium yoelii 41-2 protein antigen-related (a.a.18 to 115) | Q7RE91 | 2 µg | 800 | |
RPL0621 | cDNA-Plasmodium yoelii Protective antigen-related (a.a.21 to 316) | Q7RGF9 | 2 µg | 1770 | |
RPL0622 | cDNA-Plasmodium yoelii Ring-infected erythrocyte surface antigen (a.a.61 to 460) | Q7R903 | 2 µg | 2394 | |
RPL0623 | cDNA-Plasmodium yoelii Ring-infested erythrocyte surface antigen (a.a.61 to 460) | Q7RLL4 | 2 µg | 2394 |
Plasmodium yoelii cDNA and recombinant antigen
Malaria is a life-threatening disease caused by the Plasmodium parasite. While there are five species of Plasmodium that can cause malaria in humans, Plasmodium yoelii is commonly used as a model for studying malaria in animals. Researchers have identified various antigens of Plasmodium yoelii that could potentially be targeted for malaria prevention. In this article, we will explore some of these antigens in detail and how they can be used to prevent malaria.
Nigeriensis Erythrocyte-Binding-Like Protein:
The nigeriensis erythrocyte-binding-like protein (NEBL) is a protein found on the surface of Plasmodium yoelii. It plays a crucial role in the binding of infected red blood cells to uninfected red blood cells, which allows the parasite to evade the immune system. By targeting NEBL, researchers hope to disrupt this binding process and prevent the parasite from spreading.
Apical Membrane Antigen-1:
Another important antigen of Plasmodium yoelii is the apical membrane antigen-1 (AMA-1). This antigen is found on the surface of the parasite and is involved in the invasion of red blood cells. By targeting AMA-1, researchers hope to prevent the parasite from entering red blood cells, which could ultimately prevent the development of malaria.
Transmission-Blocking Target Antigen S230:
The transmission-blocking target antigen S230 (TBS230) is another promising target for malaria prevention. This antigen is involved in the development of the sexual stage of the parasite, which is necessary for transmission between hosts. By targeting TBS230, researchers hope to prevent the parasite from reaching its sexual stage and ultimately prevent transmission.
Processed Variable Antigen-Related:
The processed variable antigen related (PvARP) protein is found on the surface of Plasmodium yoelii and is involved in the binding of infected red blood cells to uninfected red blood cells. By targeting PvARP, researchers hope to disrupt this binding process and prevent the parasite from spreading.
Recombinant Protein-Plasmodium Yoelii Octapeptide-Repeat Antigen (A.a.61 to 460):
The recombinant protein-Plasmodium yoelii octapeptide-repeat antigen (a.a.61 to 460) (PyOPA) is a promising vaccine candidate for malaria prevention. This antigen is found on the surface of the parasite and is involved in the invasion of red blood cells. By targeting PyOPA, researchers hope to prevent the parasite from entering red blood cells, ultimately preventing the development of malaria.
Tryptophan-Threonine-Rich Antigen:
The tryptophan-threonine-rich antigen (TTRA) is another antigen found on the surface of Plasmodium yoelii. This antigen is involved in the invasion of red blood cells and is a promising target for malaria prevention.
STARP Antigen, pAg-3, Erythrocyte Membrane-Associated Antigen, Synthetic Antigen, 56A, C-13 Antigen-Related, S-Antigen Protein, Seroreactive Antigen BMN1-9B-Related, C-13 Antigen, 1-Py230, Ookinete Surface Antigen-Like Protein Pfs28:
Overview of the Key Proteins of Plasmodium Yoelii:
The Plasmodium Yoelii Octapeptide-Repeat Antigen (a.a.61 to 460) is a surface protein of the malaria parasite that plays a critical role in the invasion of red blood cells. Erythrocyte-Binding-Like Protein (EBL) is another essential protein that binds to red blood cells and facilitates invasion by the malaria parasite.
Apical Membrane Antigen-1 (AMA-1) is a surface protein of the malaria parasite that is expressed throughout the life cycle of the parasite and is involved in the invasion of red blood cells. Transmission-Blocking Target Antigen S230 (TBSA) is another surface protein of the malaria parasite that plays a critical role in blocking the transmission of the parasite from one host to another.
Processed Variable Antigen-Related (PvRBP) is a family of surface proteins that are involved in the invasion of red blood cells by the malaria parasite. Tryptophan-Threonine-Rich Antigen (TTRA) is another surface.
Plasmodium Yoelii’s cDNA and recombinant antigens can be used to detect the presence of the parasite in a sample, as well as to track its activity over time. These cDNA and antigens can be used to develop a diagnostic test for malaria, as well as to develop vaccines and therapeutics that can protect against the disease. Additionally, the cDNA and antigens can be used to identify new strains of the parasite, which can help with the development of new treatments.
The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.
Get the Latest News and Updates by Email
6393 Nancy Ridge Dr. Suite A
San Diego, CA 92121 USA
Fax: +1-858-909-0057
Get the Latest News and Updates by Email
© 2023 Bioclone Inc. All Rights Reserved.
Magnetic Beads Make Things Simple